Immunoinformatics-designed mRNA vaccine candidate against **Trypanosoma brucei** achieves **100% global population coverage** and robust in-silico immune responses.

Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei, remains a devastating parasitic disease with significant global health impact. Despite its severity, there is currently no FDA-approved vaccine available for HAT prevention, leaving a critical gap in public health strategies. Traditional vaccine development faces challenges due to the parasite's complex life cycle and antigenic variation. This necessitates innovative approaches like reverse vaccinology, which leverages genomic and proteomic data to identify promising vaccine targets and design novel candidates, aiming to overcome the limitations of conventional methods and accelerate the development of effective preventative measures.

Researchers utilized a reverse vaccinology approach to design a novel mRNA vaccine candidate against Trypanosoma brucei. They targeted key parasite proteins: variant surface glycoprotein, heat shock protein 70, and vacuolar transporter chaperone complex, aiming to predict immunogenic, non-allergenic, and non-toxic peptide epitopes. The in-silico vaccine candidate was rigorously evaluated for its population coverage, biophysical attributes, and structural stability. Molecular docking, MD simulation, and MM-GBSA analyses were employed to assess receptor binding affinity and complex stability, specifically with TLR-2 and TLR-4. Further steps included codon optimization for expression in Escherichia coli (strain K12) using pET-28a(+) and in-silico cloning. Finally, immune simulations predicted both humoral and cellular immune responses, while MFE analysis assessed mRNA integrity.